AGM/EGMMay 26, 2026, 10:06 AM
Fresenius Medical Care Completes €1B Buyback, Cancels 24.8M Shares, Approves Dividend
AI Summary
Fresenius Medical Care held its Annual General Meeting, where shareholders approved a dividend of EUR 1.49 per share for fiscal year 2025. The company announced the successful completion of its €1.0 billion share buyback program, which repurchased 24.8 million shares, and granted a new authorization for future treasury share acquisitions. Following the AGM, the Management Board resolved to cancel 24,848,819 treasury shares, reducing the share capital by EUR 24,848,819.00. The company also highlighted strong financial performance in 2025, including 8% organic revenue growth and an increased operating margin of 11.3%, alongside the US FDA approval and ongoing commercial launch of its 5008X CAREsystem.
Key Highlights
- Shareholders approved a dividend of EUR 1.49 per share for fiscal year 2025, up from EUR 1.44 in 2024.
- Successfully completed a €1.0 billion share buyback program, repurchasing 24.8 million shares (8.5% of capital).
- Management Board granted new authorization to acquire and use treasury shares for five years.
- Resolved to cancel 24,848,819 treasury shares, reducing share capital by EUR 24,848,819.00.
- Post-cancellation, share capital amounts to EUR 268,564,630.00, divided into 268,564,630 shares.
- Organic revenue growth reached 8% in 2025 at constant currency, with positive contributions from all segments.
- Group operating margin increased to 11.3% in 2025, up from 7.9% three years prior.
- Net leverage ratio reduced to 2.5 times by end of 2025, down from 3.4 times in 2022.
- US FDA approved the hemodiafiltration-capable 5008X CAREsystem in 2025, with full commercial launch underway in 2026.
Price Impact
More from FMS